Catechol-o-methyltransferase polymorphisms predict opioid consumption in postoperative pain.

Area of Science:

• Pharmacogenetics
• Nephrology
• Pain Management

Background:

• Previous research linked the catechol-O-methyltransferase (COMT) rs4680 polymorphism to opioid consumption in chronic cancer pain.
• This study investigates COMT rs4680 and rs4818 polymorphisms' role in acute postoperative opioid use following nephrectomy.

Purpose of the Study:

• To determine the association between COMT rs4680 and rs4818 genotypes and opioid consumption in the acute postoperative period after nephrectomy.
• To explore the relationship between these genetic variants and pain scores, as well as emesis medication use.

Main Methods:

• 152 patients undergoing nephrectomy had opioid consumption and pain scores monitored for 48 hours post-surgery.
• Genotyping for COMT rs4680 and rs4818 was performed using polymerase chain reaction on extracted DNA.
• General linear model regression analysis, with Bonferroni correction, was used to assess genotype-opioid consumption associations.

Main Results:

• Patients with the COMT rs4680 Val/Val genotype consumed 36% more opioids in the first 24 hours compared to Met/Met homozygotes (P=0.009).
• Higher opioid consumption was observed in Val/Val homozygotes compared to Met/Met homozygotes for COMT rs4680 in the 6- to 48-hour postsurgery period.
• The COMT rs4818 CC genotype was associated with increased emesis medication use (P=0.035), and the GG genotype showed different opioid consumption in the first 6 hours compared to CG heterozygotes (P=0.02).

Conclusions:

• The COMT rs4680 genetic variant is significantly associated with variations in postoperative opioid consumption after nephrectomy.
• The COMT rs4818 polymorphism shows potential utility in predicting postoperative emesis medication requirements.